strike One: Kevetrin
strike Two: Brilacidin skin infections and oral mucositis
strike Three: Brilacidin COVID 19

Leo does it again!

lets go 6!

Moving sideways no clear direction as to where the price should go.

nice

https://www.abstractsonline.com/pp8/#!/9045/presentation/9694

Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting
05/05/2020

https://investors.exicuretx.com/news/news-details/2020/Exicure-to-Present-AST-008-Updates-at-2020-AACR-Virtual-Annual-Meeting/default.aspx

long term trend shows slight positive trend.

a slight upward trend continues

HINGHAM, Mass., April 1, 2020 – Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of Aileen Stockburger to the Company's Board of Directors, effective April 1, 2020. Ms. Stockburger is an experienced executive and consultant with extensive expertise in strategizing, managing and closing sizable, complex worldwide mergers and acquisitions, licensing agreements and divestitures, as well as expertise in business development, strategic planning and finance.



“We are excited to have Aileen join us and strengthen our leadership team’s core capabilities, as her strategic track record and vast industry network will add tremendous value to the organization”, commented Harel Gadot, CEO, President and Chairman. “Her proven experience in merger and acquisition transactions as well as the formation and execution of strategic collaborations across the industry, will greatly enhance the Company’s ability to achieve its strategic growth objectives.”



During her almost 30 years at Johnson & Johnson, Ms. Stockburger held several business development and finance roles in Medical Devices, Corporate and Consumer. She served as Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities. While in that role, she played leading and significant roles in over $70 billion worth of transactions, including: Johnson and Johnson’s acquisition of Synthes, as well as Pfizer Consumer HealthCare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Mitek, Kodak Clinical Diagnostics and Neutrogena. Before joining Johnson & Johnson, Aileen spent three years at PriceWaterhouse Coopers, where she earned her CPA certification. She received her BS and MBA from the Wharton School, University of Pennsylvania



“Throughout my career I have sought out opportunities that allow me to use my specific skills to help effect meaningful change and impact to the healthcare market,” commented Ms. Stockburger. “I have watched Microbot Medical the past few years, albeit from a distance, and my enthusiasm to join the Board at this specific time is due to its progress developing highly advanced and revolutionary robotic systems that will transform the future of healthcare. I believe that my expertise, combined with Microbot’s assets and ambition, will allow us to address new and emerging growth markets.”

The downtrend seems to be exhausting for MBOT, but general market conditions are bad. Results for SCS are due for first quarter 2020.

Large volume today, expectations around SCS results could be the driver. 12 is an important barrier.

Microbot Medical Bologna presention.

O69 Biocompatibility of the novel microbot medical SCS shunt catheter
James P McAllister II1, Leandro Castaneyra-Ruiz1, Albert M Isaacs1, Michael Talcott1,2, Simon Sharon3, Or Samoocha3, Eran Cohen3, Ian Boader3, Carolyn A Harris4, Hezi Himelfarb3
1Department of Neurosurgery, Division of Pediatric Neurosurgery, Washington University School of Medicine, St. Louis, United Sates; 2Division of Comparative Medicine, Washington University School of Medicine, St. Louis, United Sates; 3Microbot Medical Ltd, Caesarea, Israel; 4Department of Chemical Engineering, Wayne State University, Detroit, United Sates

Correspondence: James P McAllister II
Fluids and Barriers of the CNS 2018, 15(Suppl 2):O68
Introduction: Since occlusion of ventriculoperitoneal shunt (VPS) catheters continues to be a major cause of treatment failure in hydrocephalus patients, Microbot Medical, Inc. has designed the self-cleaning ventricular catheter (SCS) to resist catheter obstruction. Following promising in vitro and ex situ studies, preclinical evaluations of the SCS are needed, with an initial focus on biocompatibility.
Methods: Hydrocephalus was induced in 30-day old piglets by percutaneous intracisternal injection of 25% kaolin. After ventriculomegaly had developed for 3–44 days, standard VPS (n?=?1) and SCS (n?=?4) catheters were implanted using routine surgical procedures. The Microbot activation coil was placed into a subcutaneous pocket behind the left ear and distal catheters were tunneled subcutaneously and inserted into the peritoneal cavity. Animals were monitored for neurological deficits, ventriculomegaly, and sacrificed at 5–49 days post-shunt (median 15d). Fixed tissue blocks containing the catheter path were processed for histopathology and immunohistochemistry.
Results: Preliminary observations indicate that unactivated Microbot catheters exhibit the same neural tissue reaction as the standard commercial catheter in current clinical practice, although ventriculomegaly increased somewhat after shunting (ventricular volume 2774 mm3 vs 4051 mm3). Both types of catheters were ensheathed by a very thin capsule of collagenous and astrocytic tissue as they passed through brain tissue or contacted the ependyma. Adjacent white matter exhibited a mild inflammatory reaction that extended only 0.2–1.0 mm beyond the surface of the catheter.
Conclusions: The inflammatory reaction to the Microbot catheter appeared to be no different than the reaction to the standard catheter.

O70 Development of a piglet model of hydrocephalus for endoscopic third ventriculostomy
James P. McAllister II1, Michael Talcott2, Albert M. Isaacs1, Leandro Castaneyra-Ruiz1, Alexis Hartman1, David D. Limbrick Jr1
1Department of Neurosurgery, Division of Pediatric Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, United States; 2Division of Comparative Medicine, Washington University School of Medicine, St. Louis, Missouri, United States

Correspondence: James P. McAllister II
Fluids and Barriers of the CNS 2018, 15(Suppl 2):O69
Introduction: Large, clinically-relevant animal models of hydrocephalus in which neurosurgical devices and novel procedures could be tested are lacking. To meet this unmet need, we have developed a porcine model of juvenile obstructive hydrocephalus, and now report our experience in performing endoscopic third ventriculostomy (ETV) on this model.
Methods: Hydrocephalus was induced in 30-day old piglets by percutaneous intracisternal injections of 25% kaolin. Pre- and post-kaolin, and pre- and post-treatment (ventriculoperitoneal shunting and ETV), anatomic MRIs were obtained to document ventriculomegaly and guide the neurosurgical procedures. Animals survived 1–84 days (median 41) post-kaolin and 17 days (median 18) post-shunt; to date the ETV case was a terminal procedure.

Results: Lateral ventricle volumes progressed from 1291?+?188 mm3 SEM pre-kaolin to 2455?+?1067, 2821?+?1139, 2280?+?1836, and 3538?+?2043 at post-kaolin days 1–5, 8–15, 22–29, and 42–69, respectively. Ventriculomegaly continued to progress post-shunt (mean 4051 mm3). ETV was performed successfully using standard neurosurgical procedures; i.e. frontal approach, visualization of the foramen of Monro (FoM), and opening the floor of the 3rd ventricle with balloon expansion. The piglet survived the procedure and after brain fixation via cardiac perfusion the path through the FoM and the ETV could be confirmed grossly with minimal damage to adjacent tissue.
Conclusions: The juvenile piglet represents a good, clinically-relevant large animal model of hydrocephalus that is amenable to ventricular shunting and ETV. Cauterization of the choroid plexus also seems feasible.

Price movement improving. Could be back to 10 next week.

The company has not released results on the SCS. Possible scenarios are that the results were not as expected and the company will just not disclose them. Other thoughts, results are not ready or the results were good and the company is already discussing a deal, and is under a quiet period.

Mr Gadot seems prone to always announce advances with a lot noise.

Presentation link https://microbotmedical.com/presentation-resources/

How the investment community perceives the value of Liberty will be reflected most likely in the price in the following weeks.

Momentum around the presentation is built. Price movements after monday will reflect the first reaction over the possibilities of Liberty of becoming a success.

News on SCS can be expected anytime. Volume has been unusually high. Positive news could make the price increase further.

Closing price was neither HOD nor HOW but was a positive signal.

Messages are to be about the company, the stock or other members opinion. Opinions about another board member thoughts, are not be addressed in a personal manner.

Expectations and anticipation will increase as the 13th is closer. So should the price. Maybe 14 to 16 price levels. Soon after, i.m.o., if news about SCS are not available the price should retest the $10 levels.

MBOT Liberty presentation will be on the 13th. Thanks for the info Fly.

I was a volunteer firefighter for 16 years!

Good volume for the week. As expectation for the Liberty presentation increase so also may the price.

News on SCS are still pending. I believe more financing announcements will be made once results are made public.

For a medical device to be approved by the FDA, time wise, this is generally shorter than for medications, that can take more than 10 years.

In this case, first, the FDA has to assign a medical device class to the SCS, this is yet unclear. What we do know, is that results from studies are soon to come and the presubmission phase is closer everyday.

Generally speaking the road to approval has 4 stages. We are at stage 1-2. Depending on the class the SCS is assigned maybe another 2 to 3 years. Or less, it will depend on the class.

Regarding Liberty, we are still far. I believe.


I.M.O. a buyout is possible. The technology around devices developed by Dr. Moshe Shoham is highly respected in the world. As an example Mazor Robotics. If SCS confirms its initial results, certainly this becomes even more possible. Again I.M.O.

But don't be surprised if results are good and yet another financing is announced. Developing medical devices is very expensive and management has expressed that having enough resources is a priority.

As you mentioned the team has vast experience, and definitely have a different vision of what robotics can do in the medical field.

.

A very difficult question to answer. SCS was the most publicize product in terms of where this company was regarding the approval needed from FDA. Now LIberty adds to the portfolio of products.

The market seems to be waiting for confirmation about these products technology in order to push the price further.

An announcement regarding SCS is probable soon. Once SCS proves merit most likely the price will surge again. Yet another finance announcement is also possible.

Personally $35 per share within the next two years is my expectation.

The dilution is close to 20% of the total shares. The price correction is already ongoing.

The first milestone regarding SCS is yet to be announced, I expect it to be within the next 30 days.

HINGHAM, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 912,858 shares of its common stock, at a purchase price per share of $10.50, priced at-the-market under Nasdaq rules.

The closing of the offering is expected to occur on or about December 27, 2019, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately $9.59 million. Microbot currently intends to use the net proceeds from this offering for the continuous development and regulatory activities for its SCS device for the treatment of hydrocephalus and NPH; continue the development of the Company’s LIBERTY robotic system, including its expansion through addition of complementary assets to it either through internal development, in-license or acquisitions; expand and develop additional applications deriving from its existing IP portfolio, either through internal development, in-license or acquisition; and for working capital and other general corporate purposes.

The shares of common stock are being offered by Microbot pursuant to a “shelf” registration statement on Form S-3 that was originally filed on March 31, 2017 and declared effective by the Securities and Exchange Commission (“SEC”) on April 14, 2017 and the base prospectus contained therein (File No. 333-217076). The offering of the shares of common stock is being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying base prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Microbot Medical, Inc.

Microbot Medical Inc. (MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed with the SEC, which are or will be available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Cash is partially restricted due to an ongoing dispute. 10 more months at the present burn rate is probable.

https://www.sec.gov/Archives/edgar/data/883975/000149315219017399/form10-q.htm#a_001

Strong after market price movement. 13.00 the price. We may have a new round of financing announcement as cash is needed in order to develop further the product portfolio.

A totally unexpected shift of events for me today, as I thought news to come would be related to another product, the SCS.

What is the real value of MBOT taking in consideration a successful SCS?

Maybe 1 B?

Microbot Medical to Unveil World’s First Fully Disposable Robotic System for Endovascular Procedures
GlobeNewswire GlobeNewswire•December 23, 2019
Live Demonstration Planned for Monday, January 13, 2020, in San Francisco

Breakthrough technology features compact design, remote operation capabilities and an integrated “One & Done” tool to democratize endovascular procedures
HINGHAM, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) today announced the revealing of LIBERTYTM, the world’s first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular procedures. The LIBERTY robotic system features a unique compact design with the capability to be operated remotely, reduce radiation exposure and physical strain to the physician, as well as the potential to eliminate the use of multiple consumables through its “One & Done” capabilities. Microbot is set to publicly display and demonstrate LIBERTY to investors, journalists and healthcare industry leaders on Monday, January 13, 2020, in San Francisco.


“LIBERTY is set to revolutionize the way surgical robotics are being used in endovascular procedures, by eliminating the need for capital equipment, reducing radiation exposure and aiming to streamline the use of disposables during these complex procedures,” commented Harel Gadot, Chief Executive Officer, President, and Chairman. “In addition, with LIBERTY’s remote operation as well as its “One & Done” capabilities, we believe it has the potential to be the first system to democratize endovascular interventional procedures.”

LIBERTY is set to revolutionize the way surgical robotics are being used in endovascular procedures, by eliminating the need for capital equipment, reducing radiation exposure and aiming to streamline the use of disposables.
-Harel Gadot, CEO of Microbot.

Dr. Eyal Morag, an ABR certified Interventional Radiologist and Chairman of Radiology and Nuclear Medicine at Assuta Ashdod Medical Center in Israel, will be performing the live demonstrations highlighting the unique capabilities of LIBERTY.

“I believe LIBERTY will be welcomed by the interventional community due to its clinical and technical benefits in various subspecialties, such as neurovascular, cardiovascular and peripheral vascular interventions,” commented Dr. Morag. “The system set up is easy and straightforward, and it offers intuitive remote operation capabilities. These features are designed to reduce radiation exposure and eliminate physical strain on the physicians. Lastly, I believe it will democratize vascular procedures by shortening the physician’s learning curve.”

Unveiling/Demonstration Event & Webcast Video

To attend the LIBERTY unveiling and demonstration event on Monday, January 13, at 7:00 am PT, please contact Michael Polyviou at 732-933-2754 or mpolyviou@evcgroup.com.

Members of the media should contact Erich Sandoval at 212-867-1762 or erich.sandoval@finnpartners.com.

Monday, January 13, at 10:00 am ET
The full presentation of the unveiling and demonstration will be available and may be accessed in the ‘Investors’ section of the Company’s website at www.microbotmedical.com.

Additionally, the Company will be hosting One-on-One meetings in San Francisco on Monday, January 13, beginning at 9:00 am PT, through Wednesday, January 15, at 3:00 pm PT. To schedule a One-on-One meeting and a private demonstration, please contact Michael Polyviou at 732-933-2754 or mpolyviou@evcgroup.com.

Weakness most likely will continue. We may see the high 4s or low 5s levels again.

https://www.sec.gov/Archives/edgar/data/883975/000149315218016474/forms-1a.htm#t_007

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549



Re: Microbot Medical Inc.
Request to Withdraw Registration Statement on Form S-1
File No.: 333-228285


Ladies and Gentlemen:



Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Microbot Medical Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Company’s above-referenced Registration Statement on Form S-1 together with all exhibits and amendments thereto (collectively, the “Registration Statement”). The Registration Statement was initially filed with the Commission on November 8, 2018.



The Company is requesting to withdraw the Registration Statement because it does not intend to proceed with the planned registered offering of the securities covered under the Registration Statement at this time. The Registration Statement has not been declared effective by the Commission, and no securities were sold or will be sold under the Registration Statement. Therefore, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477 under the Securities Act.



The Company requests that, in accordance with Rule 457(p) promulgated under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.



Very truly yours,

Microbot Medical Inc.

By: /s/ Harel Gadot
Name: Harel Gadot
Title: CEO, President and Chairman

Good volume. After hours trading also important with a high of 8.24, ending at 7.50. Volume also high.

My expectation is that, a positive an important news will be released and soon after new financing agreements announced.

Hopefully above the price of 10.

Reducing dialysis shunt stenosis i.m.o could be even a greater driver than SCS. If SCS is success as I expect, the speed for developing other products will increase.

Very very large volume move today, not based on news to my knowledge. Maybe soon. If news are related to results we could see a continued price increase, but if related to a patent approval or similar, expect a pullback.

The pullback would mean that price settles again below 6 or even 5 in the short term.

As an example of previous price patterns, check price movements around announcements(Dialysis shunt stenosis news 24.7.19, Working prototype 05.09.19)

Breaking 10 will have to happen based on a powerful and important event as many shares were financed at that price.

Volume, price and expectations increasing.

Microbot could yet again surpass 10 when news break. But, imo very very unlikely that the price will get to 20 even with news. MBOT continued solid results could make it a 150 stock. But in years time. Many trials, approvals and financing are needed. Are robots have multiple possible applications but need to prove merit.

Microbot could yet again surpass 10 when news break. But, imo very very unlikely that the price will get to 20 even with news. MBOT continued solid results could make it a 150 stock. But in years time. Many trials, approvals and financing are needed. Are robots have multiple possible applications but need to prove merit.

Microbot could yet again surpass 10 when news break. But, imo very very unlikely that the price will get to 20 even with news. MBOT continued solid results could make it a 150 stock. But in years time. Many trials, approvals and financing are needed. Are robots have multiple possible applications but need to prove merit.

6.10, 7.40 and 10 are the prices that must be surpassed to provide very strong support.

Volume and price increasing. Possible behaviour in the stock price is that of july and september 2019, fast increase when the news is posted and then a decline. Also possible, another round of financing when news is released.

More upside than down side at this time. The clock is ticking towards results! Volume seems to be improving.

Good support for the current price, biggest down risk is around 4.54.